DIA China 2026
Following the tremendous success of DIA China 2025, which brought together 8,000+ global drug R&D professionals, 200+ exhibitors, and drug agencies from 30+ countries and regions, we are thrilled to announce the DIA China 2026 Annual Meeting! Mark your calendars for this premier drug development life science event, taking place from May 13 – 16 (Biotech Day and Pre-conference Training on May 13), 2026 in Shanghai Pudong.
Clario is presenting and exhibiting at this year’s conference, and we’d love to meet up! Stop by our booth #B12 or reach out through the form below and we’ll be in touch to set up a time to meet and share how we can provide the expertise and tools needed to achieve your research goals efficiently and effectively.
Session information:
Session 1
Date: May 16, 2026
Time: 11:35 – 12:00 CET
Title: Decoding Disease Biology: Novel Neuroimaging Biomarkers in Clinical Development
Focusing on key bridges from models to early development of central nervous system diseases: improving model extrapolation and population stratification, combining new mechanisms such as pathological protein transmission with digital measurement endpoints, and constructing a more sensitive framework for early translational evidence and clinical assessment.
This session covers CNS translation from models to early development-improving translatability and stratification, exploring mechanisms such as pathological protein spread, and leveraging digital measures to strengthen early translational evidence.
Speaker:
David Scott, Ph.D.
VP, Medical and Scientific Affairs, Neuroscience at Clario
David Scott, Ph.D., is Vice President, Medical & Scientific Affairs at Clario. His aim is to facilitate drug development through standardized measurement of the neural correlates of neurodegenerative and other centrally mediated diseases.
As a student at Johns Hopkins University and the University of Michigan, he employed multimodal imaging approaches, including dynamic PET and functional MRI, to study the neurobiology of placebo analgesia. At Omneuron, he developed real-time fMRI applications aimed at treating chronic pain, depression and addiction.
Since joining Clario in 2012, David’s focus has been to enable MRI and molecular imaging solutions toward safety, eligibility and therapeutic efficacy endpoints. He works with radiologists, physicists, software engineers and operational specialists on the design, execution, analysis and interpretation of neuroscience clinical trial imaging data. His motivation is to enable neuroimaging to accelerate the delivery of therapeutic benefit to patients around the world.
Session 2
Date: May 16, 2026
Time: 13:50 – 14:45 CET
Panel Discussion: In the CNS Field, Can “Accidental Success” Be Transformed into “Inevitable Normality”?
Central nervous system (CNS) drug development is at a historic crossroads. Between 2024 and 2026, the global CNS market size is projected to exceed $65 billion, with a CAGR of 4.5%-6%, annual patent activity growth of approximately 8%, and breakthrough therapies emerging one after another. Innovation and research in this field in my country are also flourishing. However, the overall failure rate remains high. How can we reduce or avoid failures in CNS drug development? To address this, this special session, based on a review of global CNS R&D progress and data-driven trends, attempts to discuss the following question: In the CNS field, can “accidental success” be transformed into “inevitable norms”? If so, where does the path lie—embracing AI and organoid-based intelligent R&D paradigms, reshaping the digital measurement system for clinical trials, returning to systems biology thinking, or reconstructing early-stage accessibility consensus? If these are insufficient, must we accept that CNS drug development is a “high-risk, minority game” and prepare for it strategically?
Panelists:
Joyce Suhy, Ph.D.
EVP and GM, Medical Imaging and Specialty Solutions at Clario
Dr. Joyce Suhy is an accomplished professional with over 30 years of experience in both operational and scientific aspects of the medical imaging field across several therapeutic areas and leads Clario’s Medical Imaging division. She has significant expertise in the field of Neuroscience and since 2001, Dr. Suhy has been at the forefront of designing and scientifically overseeing Neuroscience clinical trials that incorporate imaging endpoints. Notably, she and her team’s extensive imaging knowledge and experience have been instrumental in the development of the first and second Alzheimer’s disease-modifying drugs to receive FDA approval.
Additional panelists include:
- Fang Fang – Zhongshan Hospital
- Huaqiong Shen – Founder and CEO, Neushen
- Yaning Wang – CEO, Shanghai Ruiningkang Biomedical Technology Development Co., Ltd.
- Yan Cheng – Executive Directive, Medical, Lilly
- Jingwei Tian – Yantai University
Meet with us
Complete this form and we will reach out soon to schedule a time to connect at the event.
If you are a company wishing to collaborate with us, please stop by our booth during the conference to talk with our team.